Insights from EMPIRE-2 on Salvage Radiotherapy Decisions with Molecular Imaging

In the EMPIRE-2 trial, molecular imaging refined salvage radiotherapy decision-making for prostate cancer (exact figures not reported in source).

• EMPIRE-2 was a randomized trial evaluating molecular imaging (likely PSMA PET) to guide salvage radiotherapy after biochemical recurrence.
• The study provides insights into how advanced imaging alters clinical decisions and treatment plans.
• Further details on the study design and patient numbers were not provided in the source snippet.

RadPigeon summaries are original and for information only. They are not clinical advice.